DUX4 and facioscapulohumeral muscular dystrophy: These therapies have shown promising preclinical results in cellular and murine models of FSHD, primarily in their ability to lower DUX4 mRNA levels, reduce DUX4 target gene expression, and alleviate FSHD symptoms (Table 1, Table 2 and Table 3).